Xbrane Biopharma and Stada Arzneimittel will co-develop Xlucane, a Lucentis biosimilar, according to a press release.
Under the co-development agreement, the companies will share development expenses and profits from commercialization of Xlucane. Stada will make an upfront payment of 7.5 million euros to enter into the agreement, the release said.
Xlucane is a biosimilar drug to Lucentis (ranibizumab, Genentech), which is used to treat several eye diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion
A pivotal trial is planned to
Uncategorized